Literature DB >> 31174230

Optimal dosing of cyclophosphamide in rhabdomyosarcoma: It's complicated.

John T Lucas1, Alberto S Pappo2.   

Abstract

Entities:  

Keywords:  ARST0531; D9803; cyclophosphamide; local failure; rhabdomyosarcoma

Mesh：

Substances：

Year:  2019        PMID： 31174230      PMCID： PMC8721594          DOI： 10.1002/cncr.32205

Source DB:  PubMed          Journal:  Cancer        ISSN： 0008-543X            Impact factor:   6.860


× No keyword cloud information.
  17 in total

1.  Rhabdomyosarcoma: many similarities, a few philosophical differences.

Authors:  Sarah S Donaldson; James R Anderson
Journal:  J Clin Oncol       Date:  2005-02-22       Impact factor: 44.544

2.  Reduction of cyclophosphamide dose for patients with subset 2 low-risk rhabdomyosarcoma is associated with an increased risk of recurrence: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.

Authors:  David O Walterhouse; Alberto S Pappo; Jane L Meza; John C Breneman; Andrea Hayes-Jordan; David M Parham; Timothy P Cripe; James R Anderson; William H Meyer; Douglas S Hawkins
Journal:  Cancer       Date:  2017-02-17       Impact factor: 6.860

3.  Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease.

Authors:  W M Crist; J R Anderson; J L Meza; C Fryer; R B Raney; F B Ruymann; J Breneman; S J Qualman; E Wiener; M Wharam; T Lobe; B Webber; H M Maurer; S S Donaldson
Journal:  J Clin Oncol       Date:  2001-06-15       Impact factor: 44.544

4.  Results from the IRS-IV randomized trial of hyperfractionated radiotherapy in children with rhabdomyosarcoma--a report from the IRSG.

Authors:  S S Donaldson; J Meza; J C Breneman; W M Crist; F Laurie; S J Qualman; M Wharam
Journal:  Int J Radiat Oncol Biol Phys       Date:  2001-11-01       Impact factor: 7.038

5.  Two consecutive phase II window trials of irinotecan alone or in combination with vincristine for the treatment of metastatic rhabdomyosarcoma: the Children's Oncology Group.

Authors:  Alberto S Pappo; Elizabeth Lyden; Phillip Breitfeld; Sarah S Donaldson; Eugene Wiener; David Parham; Kristine R Crews; Peter Houghton; William H Meyer
Journal:  J Clin Oncol       Date:  2007-02-01       Impact factor: 44.544

6.  Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: children's oncology group study D9803.

Authors:  Carola A S Arndt; Julie A Stoner; Douglas S Hawkins; David A Rodeberg; Andrea A Hayes-Jordan; Charles N Paidas; David M Parham; Lisa A Teot; Moody D Wharam; John C Breneman; Sarah S Donaldson; James R Anderson; William H Meyer
Journal:  J Clin Oncol       Date:  2009-09-21       Impact factor: 44.544

7.  Cyclophosphamide dose intensification during induction therapy for intermediate-risk pediatric rhabdomyosarcoma is feasible but does not improve outcome: a report from the soft tissue sarcoma committee of the children's oncology group.

Authors:  Sheri L Spunt; Lynette M Smith; Frederick B Ruymann; Stephen J Qualman; Sarah S Donaldson; David A Rodeberg; James R Anderson; William M Crist; Michael P Link
Journal:  Clin Cancer Res       Date:  2004-09-15       Impact factor: 12.531

8.  Influence of radiation therapy parameters on outcome in children treated with radiation therapy for localized parameningeal rhabdomyosarcoma in Intergroup Rhabdomyosarcoma Study Group trials II through IV.

Authors:  Jeff M Michalski; Jane Meza; John C Breneman; Suzanne L Wolden; Fran Laurie; MaryAnn Jodoin; Beverly Raney; Moody D Wharam; Sarah S Donaldson
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-07-15       Impact factor: 7.038

9.  The Third Intergroup Rhabdomyosarcoma Study.

Authors:  W Crist; E A Gehan; A H Ragab; P S Dickman; S S Donaldson; C Fryer; D Hammond; D M Hays; J Herrmann; R Heyn
Journal:  J Clin Oncol       Date:  1995-03       Impact factor: 44.544

10.  Excessive Treatment Failures in Patients With Parameningeal Rhabdomyosarcoma With Reduced-dose Cyclophosphamide and Delayed Radiotherapy.

Authors:  John T Lucas; Alberto S Pappo; Jianrong Wu; Daniel J Indelicato; Matthew J Krasin
Journal:  J Pediatr Hematol Oncol       Date:  2018-07       Impact factor: 1.170
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.